Cherry Creek Investment Advisors Inc. Buys 4,787 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Cherry Creek Investment Advisors Inc. grew its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 8.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 62,127 shares of the company’s stock after acquiring an additional 4,787 shares during the quarter. Cherry Creek Investment Advisors Inc.’s holdings in Recursion Pharmaceuticals were worth $420,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in RXRX. Allspring Global Investments Holdings LLC bought a new stake in shares of Recursion Pharmaceuticals in the 3rd quarter valued at about $25,000. Decker Retirement Planning Inc. bought a new position in Recursion Pharmaceuticals in the 4th quarter valued at about $26,000. GAMMA Investing LLC grew its stake in shares of Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after acquiring an additional 4,948 shares in the last quarter. Farther Finance Advisors LLC lifted its position in shares of Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after buying an additional 4,091 shares in the last quarter. Finally, Amalgamated Bank increased its position in shares of Recursion Pharmaceuticals by 52.4% during the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after purchasing an additional 2,459 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently issued reports on RXRX. KeyCorp dropped their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th.

Insider Activity

In related news, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $7.64, for a total value of $87,455.08. Following the completion of the sale, the director now owns 7,066,113 shares of the company’s stock, valued at approximately $53,985,103.32. The trade was a 0.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Michael Secora sold 15,000 shares of the firm’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the transaction, the chief financial officer now owns 1,499,631 shares in the company, valued at $11,487,173.46. The trade was a 0.99 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 15.75% of the company’s stock.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX opened at $7.03 on Tuesday. Recursion Pharmaceuticals, Inc. has a 12-month low of $5.60 and a 12-month high of $15.74. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a 50-day moving average price of $6.92 and a 200 day moving average price of $6.94.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The company had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals’s revenue for the quarter was up 147.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.43) EPS. On average, sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.